Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ORGANIZATION
ORGANIZATION
- JPMA to Begin Operating New Statistical Drug Database in FY2015
March 23, 2015
- JPMA Suspends Hasegawa’s Veep Duties for Another 2 Months over CASE-J
March 20, 2015
- FPMAJ Renews Call for Changing NHI Pricing Rules for Unprofitable Drugs with Great Medical Needs
March 20, 2015
- JPWA Calls on MHLW to Narrow Down Range of Pharmacies Subjected to Medical Fee Cut Rule for Low Price Settlement Rates
March 20, 2015
- Kyokai Kenpo Aims to Increase Generic Usage Rate to 65.1%
March 20, 2015
- JHSF Calls for Tax Incentives to Promote Investment in Regenerative Medicine
March 19, 2015
- Majority of Doctors Dissatisfied with Existing Treatments for AD, Pancreatic Cancer: JHSF
March 18, 2015
- Bone-Forming Agents Most Needed for Osteoporosis in 2025: JHSF Survey
March 18, 2015
- JSGM President Calls for Generic Share Target of 80% by FY2020
March 12, 2015
- Medwatcher Accuses HPV Vaccine Makers of Violating JPMA’s Promotion Code
March 2, 2015
- JPMA to Inform Medical Institutions of New R&D Cost Disclosure Plan in April
February 20, 2015
- AJMC Announces Guidelines for Investigator-Led Clinical Trials
February 20, 2015
- PhRMA Sets to Make Direct Plea to Finance Minister to Drop Annual Price Cut Plan
February 6, 2015
- Number of Contract Sales Reps Increased to 4,148 as of Oct. 2014: CSO Association
February 4, 2015
- JPWA President Reiterates Opposition to Annual NHI Price Revisions
February 2, 2015
- IMI, WADA Sign MOU to Prevent Use of Experimental Drugs for Doping
January 30, 2015
- July-Sept. Generic Share Reaches 51.3% under New Formula: JGA
January 30, 2015
- JPMA Draft Guidelines Urge Companies to Separate Ad Reviewing Bodies from Sales Units
January 27, 2015
- Chuikyo Members Divided on Usage of Savings from NHI Price Cuts
January 26, 2015
- 3-Price Bracket Rule for Generics Causing Various Distortions, Problems: JGA President
January 23, 2015
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…